GSK: Berenberg still a buyer, TP 1820 pence
(CercleFinance.com) - On Thursday, Berenberg renewed its Buy recommendation on GSK shares, with the target price maintained at 1820 pence.
The analyst says that the pharmaceutical company continued with growth in Q2, posting better-than-expected results and raising its targets.
While highlighting weaker-than-expected sales for Shingrix, its shingles vaccine, and questions surrounding the start of sales of its RSV vaccine Arexvy, as well as the downward revision of its 2024 annual targets for vaccines, Berenberg is confident in the group's medium- and long-term outlook.
However, Berenberg notes that GSK has revised its HIV targets upwards and is optimistic about the launch of its new generation long-acting therapies before the patent expiry of its antiretroviral dolutegravir.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
The analyst says that the pharmaceutical company continued with growth in Q2, posting better-than-expected results and raising its targets.
While highlighting weaker-than-expected sales for Shingrix, its shingles vaccine, and questions surrounding the start of sales of its RSV vaccine Arexvy, as well as the downward revision of its 2024 annual targets for vaccines, Berenberg is confident in the group's medium- and long-term outlook.
However, Berenberg notes that GSK has revised its HIV targets upwards and is optimistic about the launch of its new generation long-acting therapies before the patent expiry of its antiretroviral dolutegravir.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.